Exagen Financials - Benzinga

Exagen Inc

XGNNASDAQ

Trade with Public

Trade with Public

$7.39

-0.13-1.73%

At close: Aug 28, 5:00 PM EST

$7.39

N/A

After Hours: Aug 28, 4:00 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Exagen Financials

Exagen (XGN) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Exagen Raises FY2026 Sales Guidance from $70.000M-$73.000M to $72.000M-$75.000M vs $71.560M Est

Exagen (NASDAQ:XGN) raises FY2026 sales outlook from $70.000 million-$73.000 million to $72.000 million-$75.000 million vs $71.560 million estimate.

Benzinga Newsdesk

PRO
Exagen Q2 EPS $(0.13) Beats $(0.19) Estimate, Sales $19.941M Beat $17.817M Estimate

Benzinga Newsdesk

PRO
Exagen Affirms FY2026 Sales Guidance of $70.000M-$73.000M vs $71.267M Est

Exagen (NASDAQ:XGN) affirms FY2026 sales outlook from $70.000 million-$73.000 million to $70.000 million-$73.000 million vs $71.267 million estimate.

Benzinga Newsdesk

PRO
Exagen Q1 EPS $(0.17) Beats $(0.23) Estimate, Sales $17.306M Beat $16.414M Estimate

Exagen (NASDAQ:XGN) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.23) by 26.09 percent. This is a 15 percent increase over losses of $(0.20) per share from the same

Benzinga Newsdesk

Earnings Scheduled For May 11, 2026

Benzinga Insights

Exagen Earnings Report: Q4 Overview

Benzinga Insights